From: Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
CAR generations | Signal domain | Target antigen | Associated diseases | Profile | References |
---|---|---|---|---|---|
1st | |||||
 | CD3ζ | TAG72 | Metastatic colorectal cancer | Limited persistence | [84] |
 | CD3ζ | FRα | Ovarian cancer | Limited persistence | [26] |
 | CD3ζ | L1-CAM | Metastatic neuroblastoma | Limited persistence | [85] |
2nd | |||||
 | CD3ζ + CD28/CD137 (41BB) | CD19 | B cell lymphomas | Enhanced expansion, persistence and anti-tumor effect | |
 | CD3ζ + 41BB(CD137) | IL13Rα2 | GBM | Improved anti-tumor activity and T cell persistence | [22] |
 | CD3ζ + 41BB (CD137) | FRα | Ovarian cancer | Augmented cytokine secretion and proliferation | [88] |
3rd | |||||
 | CD3ζ + CD28 + 41BB(CD137) | CD19 | ALL | Superior activation and proliferation capacity | [89] |
 | CD3ζ + CD28 + 41BB(CD137) | PMSA | – | Promoted cytokine release, T-cell survival and tumor elimination | [90] |
 | CD3ζ + CD28 + CD137 (41BB) | Mesothelin | Mesothelioma | Prolonged persistence | [30] |
 | CD3ζ + CD28 + 41BB(CD137) | CD22 | ALL | Inferior antileukemic activity | [32] |
4th | |||||
 | CD3ζ + iIL-12+ co-stimulator | CEA | CEA+ tumors | Improved antitumor efficacy | [35] |